CPTC-EGFR-10 (CAB080316)

Uniprot ID: P00533

Protein name: EGFR_HUMAN

Full name: Epidermal growth factor receptor

Tissue specificity: Ubiquitously expressed. Isoform 2 is also expressed in ovarian cancers.

Function: Receptor tyrosine kinase binding ligands of the EGF family and activating several signaling cascades to convert extracellular cues into appropriate cellular responses (PubMed:2790960, PubMed:10805725, PubMed:27153536). Known ligands include EGF, TGFA/TGF-alpha, AREG, epigen/EPGN, BTC/betacellulin, epiregulin/EREG and HBEGF/heparin-binding EGF (PubMed:2790960, PubMed:7679104, PubMed:8144591, PubMed:9419975, PubMed:15611079, PubMed:12297049, PubMed:27153536, PubMed:20837704, PubMed:17909029). Ligand binding triggers receptor homo- and/or heterodimerization and autophosphorylation on key cytoplasmic residues. The phosphorylated receptor recruits adapter proteins like GRB2 which in turn activates complex downstream signaling cascades. Activates at least 4 major downstream signaling cascade including the RAS-RAF-MEK-ERK, PI3 kinase-AKT, PLCgamma-PKC and STATs modules (PubMed:27153536). May also activate the NF-kappa-B signaling cascade (PubMed:11116146). Also directly phosphorylates other proteins like RGS16, activating its GTPase activity and probably coupling the EGF receptor signaling to the G protein-coupled receptor signaling (PubMed:11602604). Also phosphorylates MUC1 and increases its interaction with SRC and CTNNB1/beta-catenin (PubMed:11483589). Positively regulates cell migration via interaction with CCDC88A/GIV which retains EGFR at the cell membrane following ligand stimulation, promoting EGFR signaling which triggers cell migration (PubMed:20462955). Plays a role in enhancing learning and memory performance (By similarity). Isoform 2 may act as an antagonist of EGF action. (Microbial infection) Acts as a receptor for hepatitis C virus (HCV) in hepatocytes and facilitates its cell entry. Mediates HCV entry by promoting the formation of the CD81-CLDN1 receptor complexes that are essential for HCV entry and by enhancing membrane fusion of cells expressing HCV envelope glycoproteins.

Subcellular location:

Unnamed:

Cell membrane (experimental evidence) (Topo: Single-pass type I membrane protein (experimental evidence))

Endoplasmic reticulum membrane (experimental evidence) (Topo: Single-pass type I membrane protein)

Golgi apparatus membrane (Topo: Single-pass type I membrane protein)

Nucleus membrane (Topo: Single-pass type I membrane protein)

Endosome (experimental evidence)

Endosome membrane

Nucleus (experimental evidence)


NOTE: In response to EGF, translocated from the cell membrane to the nucleus via Golgi and ER (PubMed:20674546, PubMed:17909029). Endocytosed upon activation by ligand (PubMed:2790960, PubMed:17182860, PubMed:27153536, PubMed:17909029). Colocalized with GPER1 in the nucleus of estrogen agonist-induced cancer-associated fibroblasts (CAF) (PubMed:20551055).

Isoform 2: Secreted

Protein existence: Experimental evidence at protein level


Comment:

Immunohistochemistry



IHC protocol:	HIER pH6, Dilution 1:500	
IHC test staining:	No positivity was observed.	
Literature conformance:	Not consistent with gene/protein characterization data	
Literature significance:		
RNA similarity:	Very low consistency between antibody staining and RNA expression data	
RNA tissue specificity:	Low tissue specificity	
RNA tissue distribution:	Detected in many	
IHC Sibling similarity:	Other antibody shows dissimilar IHC staining pattern	

Immunofluorescence



IF Overlay:	antibody (green), anti-tubulin (red) and DAPI (blue)
IF main location:	
IF additional location:	
IF approved for publication on HPA:	No
IF in THP-1:	Negative
IF in U2OS:	Negative

Western blot

	WB Size markers (kDa):	250, 130, 100, 70, 55, 35, 25, 15, 10
•	WB Lanes:	Marker (1), RT-4 (2), U-251MG (3), Plasma (4), Liver (5), Tonsil (6)
•	WB Target weight (kDa):	15, 45, 69, 77, 121, 129, 134
	WB Validation:	Uncertain (No bands detected.)